Panacea Biotec
403.10
-8.35(-2.03%)
Market Cap₹2,520.20 Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D-2.03%
1M-5.81%
6M+24.41%
1Y+93.30%
5Y+132.23%
View Company Insightsright
Latest news about Panacea Biotec
Panacea Biotec Swings to Profit in Q1, Revenue Surges 44% 7 days ago
Panacea Biotec reported a consolidated net profit of ₹41 crore in Q1, compared to a loss of ₹158 crore last year. Revenue increased 44% to ₹1,667 crore. The company recorded an exceptional item of ₹113 crore, including ₹85.80 crore from a settlement with Apotex Inc. and ₹27.40 crore from brand sales. The vaccines segment reported revenue of ₹1,122.50 crore with a loss, while formulations generated ₹544.50 crore with a profit. The company is focusing on expanding vaccine manufacturing capacities and scaling up its nutrition and pharmaceutical formulations business.
Panacea Biotec Secures Exchange Approval for Reclassification of Three Jain Family Members Jul 29, 2025
Panacea Biotec Faces Fresh GST Demand of 70.3 Million Rupees Jul 11, 2025
Panacea Biotec May Face Challenges as US Halts Support for Global Vaccine Alliance Gavi Jun 26, 2025
Panacea Biotech's Emulsipan Adjuvant Gains Recognition in CEPI Library Jun 03, 2025
More news about Panacea Biotec
30May 25
Panacea Biotec Reports Q4 Net Loss of ₹19 Crore, Revenue Dips
Panacea Biotec's Q4 financial results show a net loss of ₹19 crore, compared to a ₹14 crore loss in the same quarter last year. Revenue decreased by 4.41% year-on-year to ₹130 crore. This marks a shift from the previous quarter's profit of ₹45 crore, indicating volatility in the company's financial performance.
23Apr 25
Panacea Biotec Secures Additional $5.20 Million UNICEF Contract, Boosting Total Order Value to $20.15 Million
Panacea Biotec has expanded its contract with UNICEF for bivalent oral polio vaccine (bOPV) supply. The initial order of 115 million doses worth $14.95 million has been increased by an additional 40 million doses valued at $5.20 million. The total contract value now stands at $20.15 million (₹171.00 crore). The additional order will be delivered in Q3 CY2025, reinforcing the company's position in the global vaccine market and contributing to polio eradication efforts.
Panacea Biotec
403.10
-8.35
(-2.03%)
1 Year Returns:+93.30%
Industry Peers
Sun Pharmaceutical
1,640.20
(+0.43%)
Divis Laboratories
6,028.00
(+0.38%)
Cipla
1,592.80
(+3.02%)
Torrent Pharmaceuticals
3,647.40
(-0.45%)
Dr Reddys Laboratories
1,276.60
(+2.51%)
Mankind Pharma
2,600.10
(+3.73%)
Zydus Life Science
985.80
(+0.25%)
Lupin
1,962.50
(+1.14%)
Abbott
32,635.00
(+0.12%)
Alkem Laboratories
5,422.00
(+0.54%)